Is thromboprophylaxis cost effective in ovarian hyperstimulation syndrome: A systematic review and cost analysis

被引:11
作者
Wormer, Kelly Comerford [1 ]
Jangda, Ayesha A. [2 ]
El Sayed, Farah A. [3 ]
Stewart, Katherine I. [4 ]
Mumford, Sunni L. [5 ]
Segars, James H. [4 ]
机构
[1] UT Ob GYN Ctr, 2010 Church St, Nashville, TN 37203 USA
[2] Ziauddin Univ, Karachi, Pakistan
[3] Amer Univ, Beirut Med Ctr, Fac Med, Beirut, Lebanon
[4] Johns Hopkins Univ, Sch Med, Dept Gynecol & Obstet, 600 North Wolfe St, Baltimore, MD 21287 USA
[5] NICHHD, Epidemiol Branch, Eunice Kennedy Shriver, NIH, 6100 Execut Blvd, Bethesda, MD 20892 USA
关键词
Ovarian hyperstimulation syndrome; Venous thromboembolism; Prophylaxis; Cost analysis; DEEP-VEIN THROMBOSIS; IN-VITRO FERTILIZATION; HEPARIN-INDUCED THROMBOCYTOPENIA; ED AMERICAN-COLLEGE; CASE-FATALITY RATES; VENOUS THROMBOSIS; PULMONARY-EMBOLISM; ANTITHROMBOTIC THERAPY; ASSISTED REPRODUCTION; THROMBOEMBOLISM;
D O I
10.1016/j.ejogrb.2018.03.028
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background: The majority of serious thromboembolic events occurring in assisted reproductive technologies (ART) are in women with ovarian hyperstimulation syndrome (OHSS). Objectives: The purpose of this study was to present a thorough review and cost analysis regarding the use of venous thromboembolism (VTE) prophylaxis in OHSS to inform clinical management. Data sources: Databases used were Pubmed and Embase, in addition to checking reference lists of retrieved articles (inception to November 2017). Methods: The systematic search strategy identified 365 titles and abstracts. Articles included in the qualitative synthesis had identified venous thrombosis incidence rates or ratios. A separate search for the cost model was conducted recognizing all associated complications of VTE. The decision tree was modeled to best fit the patient population and a sensitivity analysis was performed over a range of variables. Results: The cost of VTE event per OHSS patient not on prophylaxis was (sic)5940 (range (sic)3405 to (sic)38,727), versus (sic)4134 ((sic)2705 to (sic)23,192) per event per patient on prophylaxis, amounting to a saving of ((sic)19 to (sic)23,192) per VTE per patient. Sensitivity analysis found VTE prophyaxis to be cost effective if the incidence of VTE in the OHSS population was greater than 2.79%. Prophylactic therapy was cost effective through 16 weeks of treatment. Limitations: OHSS is infrequent and hence, the incidence of VTE in patients with OHSS is low; therefore, the data used to inform the incidence of VTE in OHSS in the model carry some uncertainty. Further, low molecular weight heparin (LMWH) has side effects therefore individualization of care must be considered. Conclusions: With the increasing incidence of infertility and requirement for ART, thromboembolism in OHSS poses a major health threat for patients. VTE prophylaxis using enoxaparin was cost effective in patients with severe OHSS over a wide range of costs and incidences. Prophylaxis was also cost effective through the completion of the first trimester of pregnancy. (C) 2018 Elsevier B.V. All rights reserved.
引用
收藏
页码:117 / 124
页数:8
相关论文
共 62 条
  • [1] Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome
    Abramov, Y
    Barak, V
    Nisman, B
    Schenker, JG
    [J]. FERTILITY AND STERILITY, 1997, 67 (02) : 261 - 265
  • [2] Obstetric outcome of in vitro fertilized pregnancies complicated by severe ovarian hyperstimulation syndrome: a multicenter study
    Abramov, Y
    Elchalal, U
    Schenker, JG
    [J]. FERTILITY AND STERILITY, 1998, 70 (06) : 1070 - 1076
  • [3] Prevention and treatment of ovarian hyperstimulation syndrome
    Al-Shawaf, T
    Grudzinskas, JG
    [J]. BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2003, 17 (02) : 249 - 261
  • [4] A POPULATION-BASED PERSPECTIVE OF THE HOSPITAL INCIDENCE AND CASE-FATALITY RATES OF DEEP-VEIN THROMBOSIS AND PULMONARY-EMBOLISM - THE WORCESTER DVT STUDY
    ANDERSON, FA
    WHEELER, HB
    GOLDBERG, RJ
    HOSMER, DW
    PATWARDHAN, NA
    JOVANOVIC, B
    FORCIER, A
    DALEN, JE
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (05) : 933 - 938
  • [5] [Anonymous], 2011, 2009 ASS REPR TECHN
  • [6] ASHRANI AA, 2009, THROMB THROMBOLYSIS, V28, P465, DOI DOI 10.1007/S11239-009-0309-3
  • [7] VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
    Bates, Shannon M.
    Greer, Ian A.
    Middeldorp, Saskia
    Veenstra, David L.
    Prabulos, Anne-Marie
    Vandvik, Per Olav
    [J]. CHEST, 2012, 141 (02) : E691S - E736S
  • [8] More on: the 'ART' behind the clot: solving the mystery
    Bauersachs, R. M.
    Manolopoulos, K.
    Hoppe, I.
    Arin, M. J.
    Schleussner, E.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (02) : 438 - 439
  • [9] Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels
    Berkowitz, DE
    White, R
    Li, DC
    Minhas, KM
    Cernetich, A
    Kim, S
    Burke, S
    Shoukas, AA
    Nyhan, D
    Champion, HC
    Hare, JM
    [J]. CIRCULATION, 2003, 108 (16) : 2000 - 2006
  • [10] Productivity Costs of Cancer Mortality in the United States: 2000-2020
    Bradley, Cathy J.
    Yabroff, K. Robin
    Dahman, Bassam
    Feuer, Eric J.
    Mariotto, Angela
    Brown, Martin L.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (24): : 1763 - 1770